{
    "info": {
        "nct_id": "NCT06254911",
        "official_title": "Window of Opportunity Study of Pre-Operative Atezolizumab (ANTI PD-L1 ANTIBODY) for Patients with Resectable HPV Related Oropharyngeal Squamous Cell Carcinoma (OPSCC)",
        "inclusion_criteria": "* The subject is >= 18 years old on the day of consent\n* Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 5 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 5 months after the last dose of study drug(s).\n* Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.\n* A male participant must agree to use a contraception as detailed in this protocol during the treatment period and for at least during the active treatment plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose] after the last dose of study treatment and refrain from donating sperm during this period.\n* The subject has a histologic or cytologic diagnosis of squamous cell carcinoma of the oropharynx, Stage 1 (T1/2 N1) Squamous Cell Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a clinical laboratory improvement act (CLIA) approved laboratory.\n* Patients must not have evidence of extensive or \"matted/ fixed\" pathologic adenopathy on preoperative imaging.\n* The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan or positron emission tomography (PET)/CT scan as appropriate, within 28 days before the first dose of therapy\n* The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document\n* Criteria related to comparator drug or background therapy, if applicable: No prior radiation above the clavicles. Patients with a history of a curatively treated malignancy must be disease-free for at least two years prior to entry on study except for carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer\n* Age >= 18 years at time of signing Informed Consent Form\n* Ability to comply with the study protocol\n* Histologically or cytologically confirmed p16+ HPV-driven OPSCC\n* Availability of a representative tumor specimen for exploratory biomarker research\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/GL) without granulocyte colony-stimulating factor support obtained within 14 days prior to initiation of study treatment\n* Lymphocyte count >= 0.5 x 10^9/L (500/GL) obtained within 14 days prior to initiation of study treatment\n* Platelet count >= 100 x 10^9/L (100,000/GL) without transfusion obtained within 14 days prior to initiation of study treatment\n* Hemoglobin >= 90 g/L (9 g/dL) obtained within 14 days prior to initiation of study treatment.\n\n  * Patients may be transfused to meet this criterion\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment with the following exceptions:\n\n  * Patients with documented liver metastases: AST and ALT =< 5 x ULN\n  * Patients with documented liver or bone metastases: ALP =< 5 x ULN\n* Serum bilirubin =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment with the following exception:\n\n  * Patients with known Gilbert disease: serum bilirubin =< 3 x ULN\n* Serum creatinine =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment\n* Serum albumin >= 25 g/L (2.5 g/dL) obtained within 14 days prior to initiation of study treatment\n* For patients not receiving therapeutic anticoagulation: international normalization ratio (INR) or activated partial thromboplastin time (aPTT) =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment\n* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Negative human immunodeficiency virus (HIV) test at screening, with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count >= 200/uL, and have an undetectable viral load\n* Negative hepatitis B surface antigen (HBsAg) test at screening\n* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Patients who meet any of the following criteria will be excluded from study entry:\n\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:\n\n  * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.\n  * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n  * Rash must cover < 10% of body surface area\n  * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n  * There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Active tuberculosis\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Patients requiring pain medication must be on a stable regimen at study entry\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) Patients with indwelling catheters (e.g., PleurX) are allowed.\n* Uncontrolled or symptomatic hypercalcemia (ionized calcium >1.5 mmol/L, calcium >12mg/dL or corrected serum calcium >ULN)\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety.\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* History of malignancy must have been treated with curative intent and must be disease free for 1 year prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix or non-melanoma skin carcinoma\n* Prior allogeneic stem cell or solid organ transplantation\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab\n* Current treatment with anti-viral therapy for HBV\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.\n  * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of study treatment. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment\n* Glomerular filtration rate < 29 mL/min/1.73 m^2 as calculated through use of the Chronic Kidney Disease Epidemiology Collaboration equation\n* An ANC < 1.5 x 10^9/L (1500/GL) with one exception:\n\n  * Patients with benign ethnic neutropenia (BEN): ANC < 1.3 x 10^9/L (1300GL) BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* The subject is >= 18 years old on the day of consent",
            "criterions": [
                {
                    "exact_snippets": "The subject is >= 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment with the following exception:",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 5 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 5 months after the last dose of study drug(s).",
            "criterions": [
                {
                    "exact_snippets": "Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 5 months after the last dose of study drug(s), even if oral contraceptives are also used.",
                    "criterion": "contraception method usage (sexually active subjects)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use barrier contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during the course of the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 5 months after the last dose of study drug(s).",
                    "criterion": "contraception method usage (subjects of reproductive potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use barrier contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agreement to use second method of birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during the course of the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential must not be pregnant at screening.",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy).",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "menopausal status",
                            "expected_value": "premenopausal"
                        },
                        {
                            "requirement_type": "capable of becoming pregnant",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence of menses in the past 12 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior hysterectomy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.",
                    "criterion": "childbearing potential despite amenorrhea",
                    "requirements": [
                        {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "cause of amenorrhea",
                            "expected_value": [
                                "prior chemotherapy",
                                "antiestrogens",
                                "low body weight",
                                "ovarian suppression",
                                "other reasons"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A male participant must agree to use a contraception as detailed in this protocol during the treatment period and for at least during the active treatment plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose] after the last dose of study treatment and refrain from donating sperm during this period.",
            "criterions": [
                {
                    "exact_snippets": "A male participant must agree to use a contraception as detailed in this protocol during the treatment period and for at least during the active treatment plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose] after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for at least during the active treatment plus an additional 90 days after the last dose of study treatment (for study treatments with evidence of genotoxicity at any dose)"
                        }
                    ]
                },
                {
                    "exact_snippets": "refrain from donating sperm during this period",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating sperm",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for at least during the active treatment plus an additional 90 days after the last dose of study treatment (for study treatments with evidence of genotoxicity at any dose)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject has a histologic or cytologic diagnosis of squamous cell carcinoma of the oropharynx, Stage 1 (T1/2 N1) Squamous Cell Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a clinical laboratory improvement act (CLIA) approved laboratory.",
            "criterions": [
                {
                    "exact_snippets": "histologic or cytologic diagnosis of squamous cell carcinoma of the oropharynx",
                    "criterion": "diagnosis of squamous cell carcinoma of the oropharynx",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologic",
                                "cytologic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage 1 (T1/2 N1) Squamous Cell Carcinoma of the oropharynx",
                    "criterion": "stage of squamous cell carcinoma of the oropharynx",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "Stage 1 (T1/2 N1)"
                        }
                    ]
                },
                {
                    "exact_snippets": "associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC)",
                    "criterion": "HPV association by p16 protein expression",
                    "requirements": [
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "immunohistochemistry (IHC)"
                        },
                        {
                            "requirement_type": "marker",
                            "expected_value": "p16 protein expression"
                        }
                    ]
                },
                {
                    "exact_snippets": "immunohistochemistry (IHC) performed by a clinical laboratory improvement act (CLIA) approved laboratory",
                    "criterion": "laboratory performing IHC",
                    "requirements": [
                        {
                            "requirement_type": "CLIA_approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have evidence of extensive or \"matted/ fixed\" pathologic adenopathy on preoperative imaging.",
            "criterions": [
                {
                    "exact_snippets": "must not have evidence of extensive or \"matted/ fixed\" pathologic adenopathy on preoperative imaging",
                    "criterion": "pathologic adenopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "extent",
                            "expected_value": "not extensive"
                        },
                        {
                            "requirement_type": "characteristics",
                            "expected_value": [
                                "not matted",
                                "not fixed"
                            ]
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "preoperative imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan or positron emission tomography (PET)/CT scan as appropriate, within 28 days before the first dose of therapy",
            "criterions": [
                {
                    "exact_snippets": "assessment of all known disease sites ... within 28 days before the first dose of therapy",
                    "criterion": "assessment of all known disease sites",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computerized tomography (CT) scan",
                                "magnetic resonance imaging (MRI)",
                                "bone scan",
                                "positron emission tomography (PET)/CT scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document",
            "criterions": [
                {
                    "exact_snippets": "The subject is capable of understanding and complying with the protocol requirements",
                    "criterion": "subject's ability to understand and comply with protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has signed the informed consent document",
                    "criterion": "informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years at time of signing Informed Consent Form",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Criteria related to comparator drug or background therapy, if applicable: No prior radiation above the clavicles. Patients with a history of a curatively treated malignancy must be disease-free for at least two years prior to entry on study except for carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer",
            "criterions": [
                {
                    "exact_snippets": "No prior radiation above the clavicles",
                    "criterion": "prior radiation above the clavicles",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a history of a curatively treated malignancy must be disease-free for at least two years prior to entry on study",
                    "criterion": "curatively treated malignancy",
                    "requirements": [
                        {
                            "requirement_type": "disease-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer",
                    "criterion": "history of carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from disease-free duration requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to comply with the study protocol",
            "criterions": [
                {
                    "exact_snippets": "Ability to comply with the study protocol",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed p16+ HPV-driven OPSCC",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "confirmation_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "p16+",
                    "criterion": "p16 status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "HPV-driven OPSCC",
                    "criterion": "oropharyngeal squamous cell carcinoma (OPSCC) etiology",
                    "requirements": [
                        {
                            "requirement_type": "HPV-driven",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Availability of a representative tumor specimen for exploratory biomarker research",
            "criterions": [
                {
                    "exact_snippets": "Availability of a representative tumor specimen",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "representativeness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for exploratory biomarker research",
                    "criterion": "exploratory biomarker research",
                    "requirements": [
                        {
                            "requirement_type": "intended use",
                            "expected_value": "exploratory biomarker research"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 90 g/L (9 g/dL) obtained within 14 days prior to initiation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 90 g/L (9 g/dL) obtained within 14 days prior to initiation of study treatment.",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lymphocyte count >= 0.5 x 10^9/L (500/GL) obtained within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Lymphocyte count >= 0.5 x 10^9/L (500/GL) obtained within 14 days prior to initiation of study treatment",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100 x 10^9/L (100,000/GL) without transfusion obtained within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100 x 10^9/L (100,000/GL)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/GL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without transfusion obtained within 14 days prior to initiation of study treatment",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/GL) without granulocyte colony-stimulating factor support obtained within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/GL)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "granulocyte colony-stimulating factor support",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with documented liver or bone metastases: ALP =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "documented liver or bone metastases",
                    "criterion": "liver or bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ALP =< 5 x ULN",
                    "criterion": "alkaline phosphatase (ALP) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with documented liver metastases: AST and ALT =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "documented liver metastases",
                    "criterion": "liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT =< 5 x ULN",
                    "criterion": "AST",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT =< 5 x ULN",
                    "criterion": "ALT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may be transfused to meet this criterion",
            "criterions": [
                {
                    "exact_snippets": "Patients may be transfused to meet this criterion",
                    "criterion": "transfusion eligibility to meet criterion",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known Gilbert disease: serum bilirubin =< 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Patients with known Gilbert disease",
                    "criterion": "Gilbert disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serum bilirubin =< 3 x ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin >= 25 g/L (2.5 g/dL) obtained within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin >= 25 g/L (2.5 g/dL) obtained within 14 days prior to initiation of study treatment",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "g/L"
                            }
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients not receiving therapeutic anticoagulation: international normalization ratio (INR) or activated partial thromboplastin time (aPTT) =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "For patients not receiving therapeutic anticoagulation: international normalization ratio (INR) ... =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment",
                    "criterion": "international normalization ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients not receiving therapeutic anticoagulation: ... activated partial thromboplastin time (aPTT) =< 1.5 x ULN obtained within 14 days prior to initiation of study treatment",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen",
            "criterions": [
                {
                    "exact_snippets": "patients receiving therapeutic anticoagulation",
                    "criterion": "therapeutic anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable anticoagulant regimen",
                    "criterion": "anticoagulant regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase (ALP) ... =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment",
                    "criterion": "alkaline phosphatase (ALP) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative human immunodeficiency virus (HIV) test at screening, with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count >= 200/uL, and have an undetectable viral load",
            "criterions": [
                {
                    "exact_snippets": "Negative human immunodeficiency virus (HIV) test at screening",
                    "criterion": "HIV test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a positive HIV test at screening are eligible provided they ... have a CD4 count >= 200/uL",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a positive HIV test at screening are eligible provided they ... have an undetectable viral load",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative hepatitis B surface antigen (HBsAg) test at screening",
            "criterions": [
                {
                    "exact_snippets": "Negative hepatitis B surface antigen (HBsAg) test at screening",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test",
            "criterions": [
                {
                    "exact_snippets": "Negative hepatitis C virus (HCV) antibody test at screening",
                    "criterion": "hepatitis C virus (HCV) antibody test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening",
                    "criterion": "hepatitis C virus (HCV) ribonucleic acid (RNA) test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "The HCV RNA test must be performed for patients who have a positive HCV antibody test",
                    "criterion": "hepatitis C virus (HCV) ribonucleic acid (RNA) test",
                    "requirements": [
                        {
                            "requirement_type": "test_performed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "if positive HCV antibody test"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "history of autoimmune-related hypothyroidism",
                    "criterion": "autoimmune-related hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on thyroid-replacement hormone",
                    "criterion": "thyroid-replacement hormone therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment.",
                    "criterion": "therapeutic oral or IV antibiotic treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "therapeutic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.",
                    "criterion": "prophylactic antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "prophylactic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell or solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell ... transplantation",
                    "criterion": "allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior ... solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Rash must cover < 10% of body surface area",
            "criterions": [
                {
                    "exact_snippets": "Rash must cover < 10% of body surface area",
                    "criterion": "rash body surface area coverage",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "% of body surface area"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-agents) within 2 weeks prior to initiation of study treatment",
                    "criterion": "systemic immunosuppressive medication treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for systemic immunosuppressive medication during study treatment",
                    "criterion": "anticipated need for systemic immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "anticipated need during study treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled or symptomatic hypercalcemia (ionized calcium >1.5 mmol/L, calcium >12mg/dL or corrected serum calcium >ULN)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled or symptomatic hypercalcemia",
                    "criterion": "hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "ionized calcium >1.5 mmol/L",
                    "criterion": "ionized calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calcium >12mg/dL",
                    "criterion": "serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "corrected serum calcium >ULN",
                    "criterion": "corrected serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 0,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:",
            "criterions": [
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only",
                    "criterion": "eczema, psoriasis, lichen simplex chronicus, or vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with psoriatic arthritis are excluded",
                    "criterion": "psoriatic arthritis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled tumor-related pain",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled tumor-related pain",
                    "criterion": "tumor-related pain",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "progression status",
                            "expected_value": "actively progressing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment",
                    "criterion": "treatment with systemic immunostimulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety.",
            "criterions": [
                {
                    "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "any active infection that could impact patient safety",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "impact on patient safety",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Active or history of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "immune deficiency",
                    "criterion": "immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "myasthenia gravis",
                    "criterion": "myasthenia gravis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "myositis",
                    "criterion": "myositis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune hepatitis",
                    "criterion": "autoimmune hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus",
                    "criterion": "systemic lupus erythematosus",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "antiphospholipid antibody syndrome",
                    "criterion": "antiphospholipid antibody syndrome",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Wegener granulomatosis",
                    "criterion": "Wegener granulomatosis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Sjögren syndrome",
                    "criterion": "Sjögren syndrome",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Guillain-Barré syndrome",
                    "criterion": "Guillain-Barré syndrome",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple sclerosis",
                    "criterion": "multiple sclerosis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with investigational therapy within 28 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with investigational therapy within 28 days prior to initiation of study treatment",
                    "criterion": "treatment with investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to Chinese hamster ovary cell products",
                    "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity ... to any component of the atezolizumab formulation",
                    "criterion": "hypersensitivity to any component of the atezolizumab formulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of study treatment. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intention of becoming pregnant during study treatment or within 5 months after the final dose of study treatment",
                    "criterion": "intention of becoming pregnant",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": [
                                "during study treatment",
                                "within 5 months after the final dose of study treatment"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months",
            "criterions": [
                {
                    "exact_snippets": "no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months",
                    "criterion": "acute exacerbations of the underlying condition requiring specified therapies",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "previous 12 months"
                        },
                        {
                            "requirement_type": "therapies_involved",
                            "expected_value": [
                                "psoralen plus ultraviolet A radiation",
                                "methotrexate",
                                "retinoids",
                                "biologic agents",
                                "oral calcineurin inhibitors",
                                "high-potency corticosteroids",
                                "oral corticosteroids"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment",
                    "criterion": "major surgical procedure (other than for diagnosis)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "other than for diagnosis"
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for a major surgical procedure during the study",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "anticipated_need",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "during the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment",
                    "criterion": "significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class II or greater cardiac disease",
                    "criterion": "New York Heart Association cardiac disease class",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "unstable arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
            "criterions": [
                {
                    "exact_snippets": "Any other disease ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "other disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "metabolic dysfunction ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "metabolic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "physical examination finding ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "physical examination finding",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical laboratory finding ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "History of leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An ANC < 1.5 x 10^9/L (1500/GL) with one exception:",
            "criterions": [
                {
                    "exact_snippets": "An ANC < 1.5 x 10^9/L (1500/GL)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Glomerular filtration rate < 29 mL/min/1.73 m^2 as calculated through use of the Chronic Kidney Disease Epidemiology Collaboration equation",
            "criterions": [
                {
                    "exact_snippets": "Glomerular filtration rate < 29 mL/min/1.73 m^2 as calculated through use of the Chronic Kidney Disease Epidemiology Collaboration equation",
                    "criterion": "glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 29,
                                "unit": "mL/min/1.73 m^2"
                            }
                        },
                        {
                            "requirement_type": "calculation_method",
                            "expected_value": "Chronic Kidney Disease Epidemiology Collaboration equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) Patients with indwelling catheters (e.g., PleurX) are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... ascites requiring recurrent drainage procedures (once monthly or more frequently)",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with indwelling catheters (e.g., PleurX) are allowed.",
                    "criterion": "indwelling catheter",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of malignancy must have been treated with curative intent and must be disease free for 1 year prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix or non-melanoma skin carcinoma",
            "criterions": [
                {
                    "exact_snippets": "History of malignancy must have been treated with curative intent",
                    "criterion": "history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "must be disease free for 1 year prior to screening",
                    "criterion": "history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "disease_free_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix or non-melanoma skin carcinoma",
                    "criterion": "malignancy type",
                    "requirements": [
                        {
                            "requirement_type": "risk_of_metastasis_or_death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "5-year OS rate",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "severe allergic anaphylactic reactions to chimeric antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "severe allergic anaphylactic reactions to humanized antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "severe allergic anaphylactic reactions to fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients with controlled Type 1 diabetes mellitus",
                    "criterion": "Type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "who are on an insulin regimen",
                    "criterion": "insulin regimen",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients requiring pain medication must be on a stable regimen at study entry",
            "criterions": [
                {
                    "exact_snippets": "Patients requiring pain medication ... must be on a stable regimen at study entry",
                    "criterion": "pain medication regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable at study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients who received mineralocorticoids (e.g., fludrocortisone) ... are eligible for the study.",
                    "criterion": "mineralocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma ... are eligible for the study.",
                    "criterion": "corticosteroid use for COPD or asthma",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency ... are eligible for the study.",
                    "criterion": "low-dose corticosteroid use for orthostatic hypotension or adrenal insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bronchiolitis obliterans",
                    "criterion": "bronchiolitis obliterans",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced pneumonitis",
                    "criterion": "drug-induced pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic pneumonitis",
                    "criterion": "idiopathic pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence_on_CT_scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab",
            "criterions": [
                {
                    "exact_snippets": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment",
                    "criterion": "live, attenuated vaccine treatment",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study treatment initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to atezolizumab treatment",
                            "expected_value": "during treatment"
                        },
                        {
                            "requirement_type": "timing relative to final dose of atezolizumab",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "months after"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with CD137 agonists",
                    "criterion": "prior treatment with CD137 agonists",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
                    "criterion": "prior treatment with immune checkpoint blockade therapies",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy types",
                            "expected_value": [
                                "anti-CTLA-4 therapeutic antibodies",
                                "anti-PD-1 therapeutic antibodies",
                                "anti-PD-L1 therapeutic antibodies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with benign ethnic neutropenia (BEN): ANC < 1.3 x 10^9/L (1300GL) BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups",
            "criterions": [
                {
                    "exact_snippets": "benign ethnic neutropenia (BEN)",
                    "criterion": "benign ethnic neutropenia (BEN)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ANC < 1.3 x 10^9/L (1300GL)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.3,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current treatment with anti-viral therapy for HBV",
            "criterions": [
                {
                    "exact_snippets": "Current treatment with anti-viral therapy for HBV",
                    "criterion": "anti-viral therapy for HBV",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.",
                    "criterion": "systemic immunosuppressant medication",
                    "requirements": [
                        {
                            "requirement_type": "dose type",
                            "expected_value": [
                                "acute, low-dose",
                                "one-time pulse dose"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease is well controlled at baseline and requires only low-potency topical corticosteroids",
            "criterions": [
                {
                    "exact_snippets": "Disease is well controlled at baseline",
                    "criterion": "disease control status at baseline",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requires only low-potency topical corticosteroids",
                    "criterion": "corticosteroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "potency",
                            "expected_value": "low-potency"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "topical"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "Patients who meet any of the following criteria will be excluded from study entry:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}